Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Capmatinib Hydrochloride | NVP-INC280-NX; INCB-28060; C2A374O70X; INC-280; INCB-028060 | Approved | Novartis Pharma Ag, Incyte Corp | Tabrecta | EU | Carcinoma, Non-Small-Cell Lung | Novartis Europharm Ltd | 2020-05-06 | Triple Negative Breast Neoplasms; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Hepatic Insufficiency; Colorectal Neoplasms; Gliosarcoma; Sarcoma; Liver Neoplasms; Adenocarcinoma of Lung; Neoplasms; Glioblastoma; Carcinoma; Carcinoma, Renal Cell; Skin Melanoma; Kidney Neoplasms; Solid tumours | Details |
Savolitinib | HM-5016504; AZD-6094; HMP-504; HMPL-504 | Approved | Hutchison Medipharma Ltd | 沃瑞沙, ORPATHYS | Mainland China | Carcinoma, Non-Small-Cell Lung | Hutchison Medipharma Ltd | 2021-06-22 | Cholangiocarcinoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Carcinosarcoma; Carcinoma, Squamous Cell; Glioma; Neoplasms, Neuroepithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Diffuse Intrinsic Pontine Glioma; Urologic Neoplasms; Kidney Neoplasms; Central Nervous System Neoplasms; Colonic Neoplasms; Kidney Diseases; Neoplasms; Rectal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Solid tumours; Medulloblastoma | Details |
Tepotinib hydrochloride hydrate | EMD-1214063; MSC-2156119; MSC-2156119J | Approved | Merck Serono | Tepmetko, テプミトコ, TEPMETKO | EU | Carcinoma, Non-Small-Cell Lung | Merck KGaA, Darmstadt, Germany | 2020-03-25 | Solid tumours; Hepatic Insufficiency; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Crizotinib | PF-1066; PF-2341066; PF-02341066; PF-002341066 | Approved | Pfizer Pharmaceuticals Ltd (China) | 赛可瑞, Xalkori | EU | Lymphoma, Large-Cell, Anaplastic | Pfizer Europe Ma Eeig | 2011-08-26 | Neuroblastoma; Neoplasm Metastasis; Neurilemmoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Granuloma, Plasma Cell; Lymphoma; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Ureteral Neoplasms; Hematologic Neoplasms; Urethral Neoplasms; Myofibroma; Prostatic Neoplasms, Castration-Resistant; Uveal melanoma; Multiple Myeloma; Urinary Bladder Neoplasms; Kidney Diseases; Neurofibromatosis 2; Neoplasms; Solid tumours | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Osteosarcoma; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Astrocytoma; Breast Neoplasms; Sarcoma, Ewing; Lymphoma; Carcinoma, Adenosquamous; Adenocarcinoma, Clear Cell; Sarcoma, Clear Cell; Medullary thyroid cancer (MTC); Cholangiocarcinoma; Prostatic Neoplasms; Neurofibroma, Plexiform; Urethral Neoplasms; Carcinoma, Neuroendocrine; Meningioma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Melanoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Neuroblastoma; Glioma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Fallopian Tube Neoplasms; Carcinoid Tumor; Neurofibromatoses; Seminoma; Carcinoma, Transitional Cell; Glioblastoma; Rejection of liver transplantation; Carcinoma, Merkel Cell; Hepatoblastoma; Pain; Pheochromocytoma; Neoplasms; Carcinoma, Renal Cell; B | Details |
Amivantamab | JNJ-372; JNJ-61186372 | Approved | Janssen Global Services Llc, Genmab A/S | RYBREVANT | Canada | Carcinoma, Non-Small-Cell Lung | Janssen Inc | 2021-05-21 | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Ensartinib Hydrochloride | X-396 | Approved | Xcovery | 贝美纳 | Mainland China | Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2020-11-17 | Histiocytosis, Langerhans-Cell; Carcinoma, Hepatocellular; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Carcinoma, Non-Small-Cell Lung; Neoplasms, Neuroepithelial; Glioma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Brain metastases; Lung Neoplasms; Histiocytic Sarcoma; Solid tumours; Neuroblastoma; Sarcoma, Ewing; Osteosarcoma; Sarcoma; Central Nervous System Neoplasms; Neoplasms; Wilms Tumor; Rhabdoid Tumor; Hepatoblastoma; Medulloblastoma; Ependymoma; Rhabdomyosarcoma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
SAIT-301 | SAIT-301 | Phase 1 Clinical | Neoplasms | Details | |
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms | Details |
LMV-12(HE003) | LMV-12(HE003) | Phase 1 Clinical | Nanchang Hongyi Technology Co Ltd | Solid tumours | Details |
Pamufetinib | TAS-115 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd | Neoplasms | Details |
NP-107 | NP107; NP-107 | Phase 1 Clinical | Shanghai Nawei Biotechnology Co Ltd | Solid tumours | Details |
Boxitinib Hydrochloride | Phase 1 Clinical | Hec Pharm Co Ltd | Stomach Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Glioma; Lung Neoplasms | Details | |
Alirinetide | GM-606; GM-607; GM-608; GM-609; GM-6; GM-600; GM-602; GM-603; GM-604; GM-605 | Genervon Biopharmaceuticals Llc | Details | ||
LM-061 | LM-061 | Phase 1 Clinical | Shanghai Lixin Pharmaceutical Research and Development Co Ltd | Solid tumours | Details |
HTI-1066 | HTI-1066 | Jiangsu Hengrui Medicine Co Ltd | Details | ||
SGX-523 | SGX-523 | Eli Lilly And Company | Details | ||
HLX-55 | HLX-55; KTN-0216 | Phase 1 Clinical | Kolltan Pharmaceuticals Inc | Solid tumours | Details |
BPI-9016 | BPI-9016; BPI-9016M | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
EMD-1204831 | EMD-1204831 | Merck Serono | Details | ||
PF-04217903 | PF-4217903; PF-04217903; PF-4217903-A | Pfizer Pharmaceuticals Ltd (China) | Details | ||
JNJ-38877605 | JNJ-38877605 | Johnson & Johnson | Details | ||
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) | The Second Hospital Of Nanjing Medical University | Details | |||
Anti-cMet SIMPLE Antibody | ARGX-111 | Argenx Se | Details | ||
Metatinib Trometamol | BMS-817378; SIM-817378 | Phase 1 Clinical | Bristol-Myers Squibb Company | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms | Details |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
Kanitinib | CX-1003 | Phase 1 Clinical | Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd | Solid tumours | Details |
CKD-702 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Carcinoma, Non-Small-Cell Lung | Details | |
Fosgonimeton | ATH-1017; NDX-1017 | Phase 3 Clinical | M3 Biotechnology | Alzheimer Disease; Lewy Body Disease | Details |
REGN-5093-M114 | METxMET-M114; REGN5093-M114 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
REGN-5093 | REGN-5093 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
BYON-3521 | BYON-3521 | Phase 1 Clinical | Byondis Bv | Solid tumours; Neoplasms | Details |
TR1801-ADC | MT-8633; TR1801-ADC | Phase 1 Clinical | Tanabe Research Laboratories U.S.A. Inc | Solid tumours | Details |
ASKC-202 | ASKC202 | Phase 1 Clinical | Solid tumours | Details | |
Recombinant plasmid-hepatocyte growth factor | Pudk-HGF | Phase 3 Clinical | Academy Of Military Medical Sciences, Wuhan Optical Valley Humanwell Biological Pharmaceutical Co Ltd | Ischemia; Peripheral Arterial Disease | Details |
Elzovantinib | TPX-0022 | Phase 2 Clinical | Turning Point Therapeutics Inc | Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
AL-2846 | AL-2846 | Phase 2 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Advenchen Laboratories Nanjing Ltd | Bone metastases; Liver Neoplasms; Stomach Neoplasms; Neurofibromatoses; Neoplasms; Pancreatic Neoplasms; Neurofibroma; Ganglioglioma; Medullary thyroid cancer (MTC); Prostatic Neoplasms; Colorectal Neoplasms; Neurilemmoma; Carcinoma, Non-Small-Cell Lung; Neurofibromatosis 1 | Details |
Emibetuzumab | LA-480; LY-2875358 | Phase 2 Clinical | Eli Lilly And Company | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
SPH3348 | SPH-3348 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Solid tumours; Neoplasms | Details |
GB-263 | GB-263; GB-263T | Phase 2 Clinical | Genor Biopharma Co Ltd | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Glesatinib | 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265; MG-90265X; MGCD-265 | Phase 2 Clinical | Mirati Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
ABN-401 | ABN-401; KDDF-201603-08 | Phase 2 Clinical | Abion Inc | Solid tumours; Neoplasms | Details |
CM-118 | CM-118 | Phase 1 Clinical | Xcovery | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Merestinib | LY-2801653; 5OGS5K699E | Phase 2 Clinical | Eli Lilly And Company | Bone metastases; Solid tumours; Biliary Tract Neoplasms; Skin Melanoma; Pancreatic Neoplasms; Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Lymphoma, Mantle-Cell; Cholangiocarcinoma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
HS-10241 | HS-10241 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours; Carcinoma; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Bafisontamab | FIT-013a; EMB-01 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Liver Neoplasms; Biliary Tract Neoplasms; Carcinoid Tumor; Stomach Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular | Details |
MCLA-129 | MCLA-129 | Phase 2 Clinical | Merus Nv | Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
TAVO-412 | TAVO-412 | Phase 1 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd | Neoplasms | Details |
EMI-137 | EMI-137; GE-137 | Phase 2 Clinical | Ge Healthcare | Esophageal Neoplasms; Colonic Neoplasms; Barrett Esophagus | Details |
GST-HG161 | GST-HG161 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Fujian Cosunter Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Carcinoma, Hepatocellular | Details |
Telisotuzumab vedotin | ABT-399; ABBV-399 | Phase 3 Clinical | Abbvie Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
XL-092 | XL-092 | Phase 3 Clinical | Exelixis Inc | Solid tumours; Carcinoma, Renal Cell; Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
RC-108 | RC-108; RC108 | Phase 2 Clinical | RemeGen Co Ltd | Solid tumours; Digestive System Neoplasms; Gastrointestinal Neoplasms | Details |
Sitravatinib | IND-155305; MG-516; MG-91516; MGCD-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Carcinoma, Squamous Cell; Mouth Neoplasms; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Hepatic Insufficiency; Ureteral Neoplasms; Kidney Neoplasms; Liposarcoma; Lung Diseases; Uveal melanoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours | Details |
Refanalin | ANG-3777; BB-3; SNV-003 | Phase 3 Clinical | Vifor Pharma Ag, Angion Biomedica Corp | Pneumonia; Myocardial Infarction; Coronavirus Disease 2019 (COVID-19); Delayed Graft Function; Acute Kidney Injury | Details |
CBT-101 | CBT-101 | Phase 1 Clinical | Solid tumours | Details | |
AMG-337 | AMG-337 | Phase 2 Clinical | Amgen Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Sarcoma, Clear Cell; Esophageal adenocarcinoma; Adenocarcinoma; Gastrointestinal Neoplasms | Details |
This web search service is supported by Google Inc.